Xiaofang Pharmaceutical announced that the cumulative deviation value of the company's stock price increase reached 20% for 3 consecutive trading days on August 31, September 1, and September 2, 2026. The company's production and operation are normal, and there is no important information that should be disclosed but not disclosed. The company is concerned about media reports related to the drug “Compound Cymbidium Tincture” under development to treat hair loss. The drug is in the preclinical research stage, and a clinical trial application still needs to be submitted to the State Drug Administration, and there is uncertainty about subsequent research and development.

Xiaofang Pharmaceutical announced that the cumulative deviation value of the company's stock price increase reached 20% for 3 consecutive trading days on August 31, September 1, and September 2, 2026. The company's production and operation are normal, and there is no important information that should be disclosed but not disclosed. The company is concerned about media reports related to the drug “Compound Cymbidium Tincture” under development to treat hair loss. The drug is in the preclinical research stage, and a clinical trial application still needs to be submitted to the State Drug Administration, and there is uncertainty about subsequent research and development.